JP MORGAN/PUT/VERTEX PHARMACEUTICALS/340/0.1/17.01.25 | Market Closed - Börse Stuttgart 10:05:56 28/06/2024 BST | ||
| 0.37 EUR | 0.00% |
|
| Current month | -51.32% | ||
| 1 month | -33.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.37 | 0.00% |
| 27/06/24 | 0.37 | -2.63% |
| 25/06/24 | 0.38 | -13.64% |
| 24/06/24 | 0.44 | +2.33% |
| 21/06/24 | 0.43 | -12.24% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 10:05 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL2HN2 |
| ISIN | DE000JL2HN23 |
| Date issued | 02/05/2023 |
| Strike | 340 $ |
| Maturity | 17/01/2025 (203 Days) |
| Parity | 10 : 1 |
| Emission price | 4.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.66 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.5 € |
| Spread % | 56.18% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
